IDXG Stock Overview
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Interpace Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.41 |
| 52 Week High | US$3.54 |
| 52 Week Low | US$0.77 |
| Beta | 0.66 |
| 1 Month Change | -6.00% |
| 3 Month Change | 29.83% |
| 1 Year Change | 28.18% |
| 3 Year Change | -81.50% |
| 5 Year Change | -80.82% |
| Change since IPO | -99.93% |
Recent News & Updates
Shareholder Returns
| IDXG | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -0.9% | -2.3% | -0.7% |
| 1Y | 28.2% | 0.6% | 22.8% |
Return vs Industry: IDXG exceeded the US Healthcare industry which returned 0.6% over the past year.
Return vs Market: IDXG exceeded the US Market which returned 22.8% over the past year.
Price Volatility
| IDXG volatility | |
|---|---|
| IDXG Average Weekly Movement | 16.0% |
| Healthcare Industry Average Movement | 7.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IDXG's share price has been volatile over the past 3 months.
Volatility Over Time: IDXG's weekly volatility has decreased from 29% to 16% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 108 | Tom Burnell | www.interpace.com |
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis and prognosis of pancreatic cancer; PanDNA, a molecular only version of PancraGEN; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer.
Interpace Biosciences, Inc. Fundamentals Summary
| IDXG fundamental statistics | |
|---|---|
| Market cap | US$5.94m |
| Earnings (TTM) | US$1.11m |
| Revenue (TTM) | US$40.21m |
5.5x
P/E Ratio0.2x
P/S RatioIs IDXG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IDXG income statement (TTM) | |
|---|---|
| Revenue | US$40.21m |
| Cost of Revenue | US$16.31m |
| Gross Profit | US$23.90m |
| Other Expenses | US$22.79m |
| Earnings | US$1.11m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.25 |
| Gross Margin | 59.44% |
| Net Profit Margin | 2.77% |
| Debt/Equity Ratio | -61.7% |
How did IDXG perform over the long term?
See historical performance and comparison